Head to head
Rapamycin against Acarbose
Two of the strongest performers in the mouse programme designed to catch false positives, tested in the same protocol. Acarbose produced one of the largest male lifespan effects there and has almost no human geroscience data at all.
Column A
RapamycinRapamycin (Sirolimus, mTOR inhibitor)
An FDA-approved mTOR inhibitor that extends lifespan in animals and is widely studied off-label at low, intermittent doses for longevity.
Column B
AcarboseAcarbose (alpha-glucosidase inhibitor)
Produced one of the largest male lifespan effects in the mouse programme built to catch false positives, and has almost no human geroscience data at all.
Side by side, on the facts we can check
| Attribute | Rapamycin | Acarbose |
|---|---|---|
| Category | Longevity | Longevity |
| FDA status | FDA-approved (Rapamune); longevity use is off-label and investigational | Approved for type 2 diabetes. The originator US product was discontinued and generics are marketed; the Canadian originator listing was cancelled post-market in 2023 with a generic available. |
| Half-life | ~60 hours | About 2 hours; acts locally in the gut with minimal systemic absorption |
| Molecular weight | 914.2 Da | 645.6 Da |
| Mechanism | Inhibits the mTOR pathway, mimicking aspects of caloric restriction and enhancing autophagy and cellular maintenance. | Competitively inhibits intestinal alpha-glucosidases, slowing the breakdown of complex carbohydrates and blunting the postprandial glucose rise. Undigested carbohydrate reaching the colon is fermented by gut bacteria, which produces the characteristic side effects and may itself contribute to the metabolic effects. |
| Human studies cited | 2 | 2 |
| Legal status, US | FDA-approved (for its labeled use), prescription only | Prescription only; approved for type 2 diabetes |
Frequently asked questions
What is the difference between Rapamycin and Acarbose?
Rapamycin: An FDA-approved mTOR inhibitor that extends lifespan in animals and is widely studied off-label at low, intermittent doses for longevity. Acarbose: Produced one of the largest male lifespan effects in the mouse programme built to catch false positives, and has almost no human geroscience data at all.
Which has stronger research evidence, Rapamycin or Acarbose?
This database does not grade compounds. It counts what was run in people: 2 of the 3 studies cited on the Rapamycin profile were human work, against 2 of 4 for Acarbose. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Rapamycin and Acarbose FDA-approved?
Rapamycin: FDA-approved (Rapamune); longevity use is off-label and investigational. Acarbose: Approved for type 2 diabetes. The originator US product was discontinued and generics are marketed; the Canadian originator listing was cancelled post-market in 2023 with a generic available..
Related posts
Blog articles that cover Rapamycin or Acarbose, newest first.
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Longevity / Sep 8, 2026 / 9 minSenolytics in 2026: Dasatinib plus Quercetin, Fisetin, and What Human Trials Have Shown
- Longevity / Sep 8, 2026 / 9 minThe Rapamycin Dosing Debate: What PEARL Tested, the Bioavailability Problem, and What Is Unproven
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.